Hepatitis C Virus Infection in Kidney Transplantation-changing Paradigms with Novel Agents

Overview

Journal Hemodial Int

Date 2018 Apr 26

PMID 29694721

Authors

Yuvaram N V Reddy

David Nunes

Vipul Chitalia

Craig E Gordon

Jean M Francis

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) is a common cause of increased morbidity and mortality in kidney transplant patients. It is associated with posttransplant glomerulonephritis, chronic allograft nephropathy, and New Onset Diabetes after Transplant (NODAT). In the past, HCV was difficult to treat due to the presence of interferon alpha-based therapies that were difficult to tolerate and were associated with adverse side-effects, such as the risk of rejection. With the advent of oral directly acting antiviral therapies, the landscape for HCV and transplantation has changed. These agents are highly effective and well tolerated with minimal side-effects. Sustained viral response rates in excess of 90% are achieved with most current treatment regimens active against all HCV genotypes. These new agents may show an improvement in graft and patient survival while essentially eliminating the risk of acute rejection from the use of prior interferon-based HCV therapies. These agents may also result in an improvement in organ allocation for HCV donor/HCV recipient transplantation. This review is meant to discuss the epidemiology of HCV, the new oral direct-acting antiviral agents (DAAs) and future opportunities for research in the field of HCV related transplantation.

References

Goodkin D, Bieber B, Gillespie B, Robinson B, Jadoul M . Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013; 38(5):405-12. DOI: 10.1159/000355615. View

Abbott K, Lentine K, Bucci J, Agodoa L, Koff J, Holtzmuller K . Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol. 2004; 15(12):3166-74. DOI: 10.1097/01.ASN.0000145439.48387.BF. View

Fabrizi F, MARTIN P, Ponticelli C . Hepatitis C virus infection and renal transplantation. Am J Kidney Dis. 2001; 38(5):919-34. DOI: 10.1053/ajkd.2001.28576. View

Bloom R, Rao V, Weng F, Grossman R, Cohen D, Mange K . Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002; 13(5):1374-80. DOI: 10.1097/01.asn.0000012382.97168.e0. View

Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour Jr H . Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386(10003):1537-45. DOI: 10.1016/S0140-6736(15)00349-9. View

Kucirka L, Singer A, Ros R, Montgomery R, Dagher N, Segev D . Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010; 10(5):1238-46. DOI: 10.1111/j.1600-6143.2010.03091.x. View

Feld J, Jacobson I, Hezode C, Asselah T, Ruane P, Gruener N . Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015; 373(27):2599-607. DOI: 10.1056/NEJMoa1512610. View

Terrault N, Adey D . The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007; 2(3):563-75. DOI: 10.2215/CJN.02930806. View

Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M . Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents. Am J Transplant. 2015; 16(5):1588-95. DOI: 10.1111/ajt.13620. View

10.

Scott D, Wong J, Spicer T, Dent H, Mensah F, McDonald S . Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010; 90(11):1165-71. DOI: 10.1097/TP.0b013e3181f92548. View

11.

Espinosa M, Martin-Malo A, Alvarez de Lara M, Gonzalez R, Rodriguez M, Aljama P . Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol. 2002; 58(2):143-50. DOI: 10.5414/cnp58143. View

12.

Carpio R, Pamugas G, Danguilan R, Que E . Outcomes of Renal Allograft Recipients With Hepatitis C. Transplant Proc. 2016; 48(3):836-9. DOI: 10.1016/j.transproceed.2016.02.050. View

13.

Carbone M, Cockwell P, Neuberger J . Hepatitis C and kidney transplantation. Int J Nephrol. 2011; 2011:593291. PMC: 3132687. DOI: 10.4061/2011/593291. View

14.

Fabrizi F, Messa P, Martin P . Health-related quality of life in dialysis patients with HCV infection. Int J Artif Organs. 2009; 32(8):473-81. DOI: 10.1177/039139880903200801. View

15.

Morales A, Liriano-Ward L, Tierney A, Sang M, Lalos A, Hassan M . Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. Clin Transplant. 2017; 31(5). DOI: 10.1111/ctr.12941. View

16.

Goetsch M, Tamhane A, Varshney M, Kapil A, Overton E, Towns G . Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios. Pathog Immun. 2017; 2(3):366-375. PMC: 5654569. DOI: 10.20411/pai.v2i3.211. View

17.

Fernandez I, Munoz-Gomez R, Pascasio J, Baliellas C, Polanco N, Esforzado N . Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol. 2017; 66(4):718-723. DOI: 10.1016/j.jhep.2016.12.020. View

18.

Fabrizi F, MARTIN P, Dixit V, Messa P . Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014; 21(5):314-24. DOI: 10.1111/jvh.12148. View

19.

Stock P, Barin B, Murphy B, Hanto D, Diego J, Light J . Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010; 363(21):2004-14. PMC: 3028983. DOI: 10.1056/NEJMoa1001197. View

20.

Lubetzky M, Chun S, Joelson A, Coco M, Kamal L, Ajaimy M . Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents. Transplantation. 2016; 101(7):1704-1710. DOI: 10.1097/TP.0000000000001618. View